Transfusion
Volume 54, Issue 6 pp. 1688-1691
ERRATUM
Free Access

CORRECTION_Lanza

First published: 09 June 2014
https://doi.org/10.1111/trf.12722

Lanza F, Lemoli RM, Olivieri A, et al. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. Transfusion 2014;54:331-9.

The authors regret the errors in all of their tables. Please see the corrected tables below.

Table 1. Baseline demographics and clinical characteristics in the total population
Variable Subgroup Total
Age (years) 55.6 ± 11.6 (17-76)
Sex 215
Male 114 (52.2)
Female 104 (47.8)
Diagnosis and mobilization strategy
MM 84 (38.5)
Chemotherapy 33 (42.0)
Steady state 46 (58.0)
NHL 108 (49.5)
Chemotherapy 41 (44.0)
Steady state 53 (56.0)
HL 23 (10.6)
Chemotherapy 5 (23.0)
Steady state 17 (77.0)
Other 3 (1.4)
Mobilization category 207
Predicted PM 64 (30.9)
Proven PM 143 (69.1)
Mobilization strategy 212
Chemotherapy 86 (40.6)
Steady state 126 (59.4)
  • * Data are reported as mean ± SD (range) or number (%).
  • † Note that not all details were available for all patients. Percentages are given accordingly.
  • ‡ According to GITMO criteria.21
Table 2. Diagnosis and mobilization characteristics by endpoint (CD34+ cells/kg or peak CD34+ cells × 106/L status)
CD34+ cells/kg CD34+ cells × 106/L
Nonmobilizer (<2 × 106cells/kg) Mobilizer (>2 × 106cells/kg) Nonmobilizer (<20 × 106 cells/L) Mobilizer (>20 × 106 cells/L)
<0.5 0.5-1 1-2 2-5 >5 <10 10-20 <20
Total population 46 (21.6) 6(2.8) 16 (7.5) 84 (39.4) 61 (28.7) 38 (19.6) 38 (19.6) 118 (60.8)
Diagnosis
NHL 29 (27.1) 5 (4.7) 11 (10.3) 62 (57.9) 28 (29.8) 19 (20.2) 47 (50)
HL 6 (26.1) 0 (0.0) 1 (4.3) 16 (69.6) 4 (20.0) 5 (25.0) 11 (55)
MM 10 (12.4) 1 (1.3) 3 (3.8) 19 (23.8) 47 (58.7) 6 (7.8) 13 (16.9) 58 (75.3)
Mobilization category
Predicted PM 14 (22.0) 49 (78.0) 18 (34) 35 (66)
Proven PM 49 (35.0) 90 (65.0) 58 (42) 80 (58)
Mobilization strategy
Chemotherapy 21 (26.0) 59 (74.0) 23 (31) 52 (69)
Steady state 37 (32.0) 80 (68.0) 49 (44) 62 (56)
Diagnosis and mobilization strategy
NHL
Chemotherapy 24 (45.0) 29 (55.0) 30 (61) 19 (39)
Steady state 12 (29.0) 29 (71.0) 14 (36) 25 (64)
HL
Chemotherapy 4 (24.0) 13 (76.0) 7 (44) 9 (56)
Steady state 2 (40.0) 3 (60.0) 1 (33) 2 (67)
MM
Chemotherapy 7 (16.0) 38 (84.0) 11 (25) 33 (75)
Steady state 7 (21.0) 26 (79.0) 8 (25) 24 (75)
  • * Data are reported as number (%).
  • † At least 4 × 106 CD34+ cells/kg (cut off for MM patients).
  • ‡ According to GITMO criteria.21
Table 3. Significant predictive factors in the total population
Endpoint Factor Categories Nonmobilizer Mobilizer p value univariate p value multivariate
CD34+ cells/kg Diagnosis NHL 45 (42.1) 62 (57.9) 0.0016 NS
HL 7 (30.4) 16 (69.6)
MM 14 (17.5) 66 (82.5)
Mobilization status Predicted 14 (22.0) 49 (78.0) NS Not considered
Proven 49 (35.0) 90 (65.0)
Mobilization strategy Chemotherapy 21 (26.0) 59 (74.0)
Steady state 37 (32.0) 80 (68.0) NS Not considered
PLTs (×109/L) Number 59 140 <0.0001 <0.0001
Mean ± SD 116.48 ± 69.83 176.52 ± 89.33
≤100 22 (49) 23 (51) 0.0013 <0.0001
>100 37 (24) 117 (76)
≤140 38 (44) 49 (56) 0.0001 <0.0001
>140 21 (19) 91 (81)
Radiotherapy No 46 (27) 122 (73) 0.028 0.044
Yes 15 (47) 17 (53)
CD34+ cells × 106/L Diagnosis NHL 47 (50) 47 (50) NS NS
HL 9 (45) 11 (55)
MM 19 (25) 58 (75)
Mobilization category Predicted 18 (34) 35 (66) NS Not considered
Proven 58 (42) 80 (58)
Mobilization strategy Chemotherapy 23 (31) 52 (69)
Steady state 49 (44) 62 (56) NS Not considered
PLTs (×109/L) Number 71 117 <0.0001 <0.0001
Mean ± SD 122.56 ± 67.54 178.32 ± 89.50
≤100 26 (60) 17 (40) 0.0005 0.0004
>100 45 (31) 100 (69)
≤143 46 (54) 39 (46) <0.0001 0.0002
>143 25 (24) 78 (76)
Fludarabine No 63 (36) 111 (64) 0.0009 0.0175
Yes 12 (80) 3 (20)
  • * Cutoff obtained by ROC curve analysis.
  • † According to GITMO criteria.21
Table 4. Significant predictive factors in the predicted PM population (n = 64)
Endpoint Factor Categories Nonmobilizer Mobilizer p value
Univariate Multivariate
CD34+ cells/kg Diagnosis NHL 10 (33) 20 (67) NS NS
HL 1 (13) 7 (87)
MM 3 (12) 22 (88)
Mobilization strategy Chemotherapy 9 (32) 19 (68)
Steady state 5 (14) 30 (86) NS Not considered
PLTs (×109/L) N 14 47 0.0052 0.043
Mean ± SD 101.71 ± 77.98 193.38 ± 109.88
≤100 7 (50) 7 (50) 0.011 NS
>100 7 (15) 40 (85)
≤103 9 (53) 8 (47) 0.0005 0.027
>103 5 (11) 39 (89)
Fludarabine No 10 (18) 47 (82) 0.0014 NS
Yes 4 (80) 1 (20)
WBCs N 14 47 0.0199 NS
Median 6.14 15.36
CD34+ cells × 106/L Diagnosis NHL 11 (44) 14 (56) NS Not estimated
HL 2 (40) 3 (60)
MM 5 (22) 18 (78)
Mobilization strategy Chemotherapy 8 (35) 15 (65)
Steady state 10 (33) 20 (67) NS
PLTs (×109/L) Number 17 34 0.046
Mean ± SD 126.18 ± 82.17 189.76 ± 113.53
≤100 6 (50) 6 (50) NS
>100 11 (28) 28 (72)
≤143 11 (55) 9 (45) 0.0084
>143 6 (19) 25 (81)
Fludarabine No 13 (28) 34 (72) 0.0033
Yes 5 (100) 0 (0)
WBCs Number 17 34 0.0021
Median 4.70 22.68
Neutrophil count (×109/L) Number 17 29 0.012
Median 3.24 8.5
  • * Cut-off obtained by ROC curve analysis.
Table 5. Significant predictive factors in the proven PM population (n = 144)
Factor Categories Nonmobilizer Mobilizer p value univariate p value multivariate
CD34+ cells/kg Diagnosis NHL 30 (43) 39 (57) 0.034 NS
HL 6 (40) 9 (60)
MM 11 (21) 41 (79)
Mobilization type Chemotherapy 12 (25) 37 (75)
Steady state 32 (40) 50 (61) NS Not considered
PLTs (×109/L) Number 45 90 0.001 0.0017
Mean ± SD 121.07 ± 67.37 163.61 ± 70.05
≤100 15 (48) 16 (52) 0.043 0.027
>100 30 (29) 74 (71)
≤129 24 (46) 28 (54) 0.012 0.0069
>129 21 (25) 62 (75)
Sex Male 21 (27) 56 (73) 0.028 NS
Female 28 (45) 34 (55)
CD34+ cells × 106/L Diagnosis NHL 36 (53) 32 (47) NS NS
HL 7 (47) 8 (53)
MM 14 (27) 38 (73)
Mobilization type Chemotherapy 15 (31) 34 (69)
Steady state 39 (48) 42 (52) NS 0.0166
PLTs (×109/L) N 54 80 0.0001 <0.0001
Mean ± SD 121.42 ± 63.09 168.91 ± 71.60
≤100 20 (65) 11 (35) 0.0017 0.0003
>100 34 (33) 69 (67)
≤142 35 (54) 30 (46) 0.0019 0.0013
>142 19 (27) 50 (73)
  • * Cutoff obtained by ROC curve analysis.

    The full text of this article hosted at iucr.org is unavailable due to technical difficulties.